Aurobindo Pharma Ltd.’s profit declined 10% in the first quarter of this financial year. The drugmaker has posted a consolidated bottom-line of Rs 825 crore, according to the financial results declared on Monday.
This is in comparison to the profit of Rs 919 crore in the same quarter of the previous fiscal year.
Revenue increased by 4% year-on-year for the three months ended June, reaching Rs 7,868 crore. Operating income, or earnings before interest, taxes, depreciation, and amortisation, fell 1% year-on-year to Rs 1,603 crore. The Ebitda margin contracted to 20.4%.
Aurobindo Pharma Q1 Highlights (Consolidated, YoY)
-
Revenue up 4% to Rs 7,868 crore versus Rs 7,567 crore (Estimate: Rs 8,196.60 crore).
-
Net profit down 10% to Rs 824.70 crore versus Rs 919 crore (Estimate: Rs 940 crore).
-
Ebitda down 1% to Rs 1,602.90 crore versus Rs 1,619.40 crore (Estimate: Rs 1,726.60 crore).
-
Margin at 20.4% versus 21.4% (Estimate: 21.06%).
This is a developing story.
. Read more on Earnings by NDTV Profit.